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The dual action of poly(ADP-ribose)
polymerase -1 (PARP-1) inhibition in
HIV-1 infection: HIV-1 LTR inhibition
and diminution in Rho GTPase
activity
Slava Rom*, Nancy L. Reichenbach, Holly Dykstra and Yuri Persidsky*
Department of Pathology and Laboratory Medicine, Temple University School of Medicine, Philadelphia, PA, USA
Multifactorial mechanisms comprising countless cellular factors and virus-encoded
transactivators regulate the transcription of HIV-1 (HIV). Since poly(ADP-ribose)
polymerase 1 (PARP-1) regulates numerous genes through its interaction with various
transcription factors, inhibition of PARP-1 has surfaced recently as a powerful
anti-inflammatory tool. We suggest a novel tactic to diminish HIV replication via PARP-1
inhibition in an in vitro model system, exploiting human primary monocyte-derived
macrophages (MDM). PARP-1 inhibition was capable to lessen HIV replication in MDM
by 60–80% after 7 days infection. Tat, tumor necrosis factor α (TNFα), and phorbol
12-myristate 13-acetate (PMA) are known triggers of the Long Terminal Repeat (LTR),
which can switch virus replication. Tat overexpression in MDM transfected with an
LTR reporter plasmid resulted in a 4.2-fold increase in LTR activation; PARP inhibition
caused 70% reduction of LTR activity. LTR activity, which increased 3-fold after PMA or
TNFα treatment, was reduced by PARP inhibition (by 85–95%). PARP inhibition in MDM
exhibited 90% diminution in NFκB activity (known to mediate TNFα- and PMA-induced
HIV LTR activation). Cytoskeleton rearrangements are important in effective HIV-1
infection. PARP inactivation reduced actin cytoskeleton rearrangements by affecting Rho
GTPase machinery. These discoveries suggest that inactivation of PARP suppresses HIV
replication in MDM by via attenuation of LTR activation, NFκB suppression and its effects
on the cytoskeleton. PARP appears to be essential for HIV replication and its inhibition
may provide an effective approach to management of HIV infection.
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Introduction
Human immunodeficiency virus (HIV)-1 crosses the blood brain barrier and infects glial cells of the
central nervous system (CNS). Human immunodeficiency virus (HIV)-1-associated neurological
disorder (HAND) is defined as cognitive, motor and/or behavioral impairments caused by HIV
replication, immune activation and release of neurotoxins in the brain that results in neuronal
injury (Ellis et al., 2011). Even though under antiretroviral therapy some individuals demonstrate
immune recovery, HAND incidence remains high and causes for that are not understood
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(Ellis et al., 2011). One current theory is that the
neurodegeneration associated with HIV-1 infection is caused
by chronic brain inflammation, concomitant with a low level of
HIV-1 replication in CNS resident macrophages and microglia
(Kraft-Terry et al., 2010; Thompson et al., 2011). Therefore,
specific tactics aiming at inflammation and HIV-1 replication
should be valuable for HAND amelioration.
Recently, poly(ADP-ribose) polymerase (PARP)-1 inhibitors
have arisen as powerful immunomodulatory and anti-
inflammatory compounds. PARP-1 (further in the text referred
to as PARP), being a member of a family of NAD-dependent
enzymes, produces approximately 80% of poly(ADP-ribose)
(PAR) in the cell (Rouleau et al., 2010). Post-translational
modification of proteins by poly(ADP-ribosyl)ation has well-
known effects on various cellular functions involving cell death,
differentiation and gene expression (Krishnakumar and Kraus,
2010). PARP, being an enzyme and a scaffold protein, is a
crucial factor of the transcriptional machinery that regulates
spatial organization of transcription-regulating supramolecular
complexes, architecture of chromatin and histone shuttling
(Krishnakumar and Kraus, 2010), thereby regulating
inflammation-associated genes. The anti-inflammatory effects
of PARP deactivation has been recently validated in animal
models of meningitis, stroke, traumatic brain injury and multiple
sclerosis (MS) (Lenzsér et al., 2007; Farez et al., 2009; Lescot et al.,
2010; Rom et al., 2015), where inhibition of PARP diminished
brain edema and decreased expression of adhesion molecules,
infiltration of leukocytes and neuroinflammation (Zhang et al.,
2004; Lenzsér et al., 2007). Previously, PARP inactivation was
shown to play a role in the HIV-1 virus cycle, where PARP
participated in HIV-1 LTR functions in U1 cells (Kameoka
et al., 1999b, 2005), competed for binding to TAR RNA with
positive transcription elongation factor b (p-TEFb) in vitro
(Parent et al., 2005), and was required for efficient HIV-1
integration in (PARP-1−/−) mouse embryonic fibroblasts (Ha
et al., 2001).
For the first time, in this study, we illustrate mechanisms
of the modulatory effects of PARP inhibition on HIV-1
infection in primary human monocyte-derived macrophages
(MDM). Our results suggest that PARP inactivation has a
dual action in its effects on HIV-1 by negative regulation of
HIV-1 LTR activity via NFκB inactivation and repressing
actin cytoskeleton machinery through effects on the
activity of small Rho GTPases. Both actin rearrangements
and LTR are critical for HIV-1 infection and transfer
of genetic material to the nucleus as well as HIV-1 gene
transcription.
Abbreviations: PARP, Poly(ADP-ribose) polymerase; NFκB, nuclear factor
kappa-light-chain-enhancer of activated B cells; ABA, 3-aminobenzamide;
AZD, AZD2281 (Olafarib); BMN, BMN-673 (Talazoparib); AIQ-5,
aminoisoquinolinone; PJ34, [N-(6-oxo-5,6-dihydro-phenanthridin-2-yl)-N,
N-dimethylacetamide hydrochloride; EB47, 5′-deoxy-5′-[4-[2-[(2,3-dihydro-
1-oxo-1H-isoindol-4-yl)amino]-2-oxoethyl]-1-piperazinyl]-5′-oxoadenosine
dihydrochloride; MDM, monocyte-derived macrophages; PMA, phorbol
12-myristate 13-acetate; FACS, fluorescence-activated cell sorting; MFI, mean
fluorescence intensity.
Materials and Methods
Reagents and Cells
The following PARP inhibitors were used: 5-
aminoisoquinolinone (AIQ) and [N-(6-oxo-5,6-dihydro-
phenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride
(PJ34) purchased from Enzo Life Sciences (Farmingdale, NY);
3-aminobenzamide (ABA), acquired from Sigma-Aldrich
(St. Louis, MO), 3H-pyrido[4,3,2-de]phthalazin-3-one,
5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-
1H-1,2,4-triazol-5-yl)-, (8S,9R)- (BMN 673, Talazoparib,
BMN) and AZD2281 (AZD, Olaparib) purchased from Selleck
Chemicals (Houston, TX), and 5′-deoxy-5′-[4-[2-[(2,3-dihydro-
1-oxo-1H-isoindol-4-yl)amino]-2-oxoethyl]-1-piperazinyl]-5′-
oxoadenosine dihydrochloride (EB47) purchased from Tocris
Bioscience (Minneapolis, MN). PARP inhibitors were used
in concentrations (ABA at 2mM, PJ34, AZD, and EB47 at
10µM, AIQ at 2µM, and BMN at 20 nM) for the period of
time indicated in the figure legends, and did not show any
toxicity (Supplementary Figure 1). Recombinant human TNFα
and PMA were purchased from R&D Systems (Minneapolis,
MN) and Sigma-Aldrich, respectively. Rho A GTPase-specific
inhibitor, CT04, and Rho GTPase switch™ activator, CN04,
were purchased from Cytoskeleton Inc. (Denver, CO). Rac1
GTPase-specific inhibitor, NSC23766 (NSC), was purchased
from EMD Chemicals (San Diego, CA).
Primary human monocytes from HIV-1 and hepatitis B
seronegative donors were obtained from the University of
Nebraska Medical Center, Department of Pharmacology and
Experimental Neuroscience, Omaha, NE, after leukopheresis
and were purified by countercurrent centrifugal elutriation
(Ramirez et al., 2008). Monocytes (1 × 106/well) were seeded
into 24-well CellBind multiwell plates (Corning) within 24 h
of isolation and maintained in Dulbecco’s modified essential
medium, high glucose (DMEM, Life Technologies, Carlsbad,
CA) supplemented with 10% heat-inactivated fetal bovine serum
(FBS), 100U/ml penicillin, 100µg/ml streptomycin, 1% non-
essential amino acids, and 1% glutamine (2mM) (complete
medium) and incubated for 7 days (Ramirez et al., 2013;
Persidsky et al., 2015). Culturemediumwas changed every 3 days.
After 7 days in suspension culture,MDMwere infected with three
strains of HIV-1, two macrophage tropic strains (M-tropic) HIV-
1ADA (Ebenbichler et al., 1995) and HIV-1JRFL (Naif et al., 2002),
or a dual-tropic HIV-189.6 strain (Yi et al., 1999) (obtained from
the AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, National Institutes of Health, Germantown, MD)
at an m.o.i. of 0.1 infectious virus particles/target cell. MDM
were either pre-treated with test compounds for 24 h or post-
treated immediately after infection with HIV-1. After 4 h HIV-1
infection, MDM were gently washed with complete medium and
treatments were replenished. MDM were then incubated, with
half medium replacement on days 3, 5, and 7 post-HIV infection.
Test compounds were replenished every 12 h. On day 7 post-
infection, culture medium was collected and stored at −80◦C
until assay for HIV-1 reverse transcriptase (RT) activity. Data
are presented as means of at least triplicate determinations
(± SEM).
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TZM-bl cells (reporter cell line) were obtained from the NIH
AIDS Research and Reference Reagent Program. TZM-bl cells
were grown in 6-well plates in DMEM containing 10% FBS,
100 units/ml penicillin, and 100µg/ml streptomycin. All cell
culture reagents (media, antibiotics, etc.) were purchased from
Life Technologies.
Plasmids and MDM Transfection
The HIV-1 LTR-luciferase reporter plasmid and its deletion
mutants were created by PCR and cloned into KpnI/BglII of
pGL3 as described previously (Rom et al., 2010). The pEYFP-
Tat101 fusion construct was cloned into the pEYFP-C1 plasmid
(Clontech, Mountain View, CA) as described (Rom et al., 2011).
Ready-To-Glow™ NFκB Secreted Luciferase Reporter plasmid
was purchased from Clontech. All transfection assays were
performed using the Lipofectamine LTX kit (Life Technologies).
The pYFP-C1 plasmid was used as an internal control for
transfection efficiency.
Reverse Transcriptase Assay
HIV reverse transcriptase (RT) activity was determined in HIV-
1 infected MDM cultures collected 3, 5, and 7 days after HIV
infection. The assay was performed as described (Ramirez et al.,
2013).
Enzyme Immunoassay for the Detection of HIV-1
p24
HIV-1 p24 antigen capture assay (Advanced Bioscience
Laboratories, Inc., Rockville, MD) was measured in tissue
culture supernatants by double antibody sandwich enzyme
immunoassay according to the manufacturer’s directions.
Single Round HIV-1 Infection and
β-galactosidase Assay
Recombinant luciferase-encoding HIV-1 virions were
pseudotyped with the envelope from HIV-1ADA as previously
described (Guo et al., 2002). The pseudotyped virus was
used for single round infectivity assays in TZM-bl cells with
the β-galactosidase staining assay (Life Technologies). The
presence of LTR-driven β-gal provides a measure of LTR
activity. TZM-bl cells were infected with pseudotyped virus for
48 h in the presence of AIQ, PJ34, or AZT. Images of stained
cells were obtained with an AxioCam HR camera attached to
an Axio Observer Z1 microscope (Carl Zeiss MicroImaging,
Thornwood, NY). AxioVision (v4.7) imaging software (Carl Zeiss
MicroImaging) was used to analyze the images. The number of
stained cells was enumerated as an average of triplicates for each
condition from two independent experiments.
Luciferase Assays
For HIV-1 LTR activity, MDM were transfected with HIV-
1 LTR-luciferase reporter plasmid and then stimulated with
TNFα or PMA for 24 h. Alternatively MDM were co-transfected
with pEYFP-Tat101 plasmid or pYFP-C1 (as a control) and
24 h later were harvested. Luciferase activity was measured
in protein extracts with the dual-luciferase reporter assay
system (Promega, Madison, WI). MDM were pretreated with or
without PARP inhibitors (PARPi) for 1 h prior to stimulation
with TNFα or PMA. Alternatively PARPi were added to the
medium 3 h post-transfection with pEYFP-Tat101 plasmid. For
NFκB activity, the plasmids, Ready-To-Glow™ NFκB Secreted
Luciferase Reporter plasmid or Ready-To-Glow™ Secreted
Luciferase Reporter plasmid, that do not have NFκB binding
sites as a control, were transfected into MDM as described
above. MDM were pretreated with or without PARPi for 1 h
prior to stimulation with TNFα or PMA for 24 h; medium
was collected and analyzed utilizing Ready-To-Glow Secreted
Luciferase Assay (Clontech, Mountain View, CA) based on
the secreted Metridia luciferase reporter according to the
manufacturer’s instructions.
CXCR4 Ligation and Cross-linking
For receptor engagement studies, MDM were suspended in
DMEM/1% FBS/L-glutamine at 5 × 106 cells/ml. Surface
CXCR4 antigen was ligated with monoclonal antibody (12G5,
eBioscience Inc., San Diego, CA) at 4◦C for 25min at 15µg/ml,
washed twice in cold DMEM, and then cross-linked with 5µg/ml
goat anti-mouse F(ab′)2 (Thermo Scientific, Rockford, IL) for
25min at 4◦C. Cells were washed twice in cold DMEM, re-
suspended in DMEM/1% FCS/L-glutamine and incubated at
37◦C, 5% CO2 for times ranging from 0min to 1 h. Reactions
were stopped by placing the cells on ice. In inhibition studies,
MDMs were pre-incubated with PARPi overnight.
FIGURE 1 | PARP inhibition decreases HIV-1 reverse transcriptase (RT)
activity and HIV-1 LTR activity in HIV-1 infected human macrophages
(MDM). RT activity assays performed on HIV-infected MDM treated with
PARPi or AZT either for 24 h prior to HIV infection (A) or immediately after (B)
HIV infection. Treatments with PARP inhibitors (PARPi) or AZT were
replenished every 12 h. The results are shown as the mean value ± SEM from
three independent experiments utilizing MDM prepared from different donors.
Data are presented as percent of HIV-only control. (**p = 0.05, ***p = 0.005,
****p < 0.0001, ns = not significant).
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Small Rho Guanosine Triphosphatase (GTPase)
Activity Assay
RhoA and Rac1 GTPase activity was measured in unstimulated
(basal) or stimulated primary MDMs (with/out pretreatment
with PARPi) by cross-linking CXCR4 receptor with antibody
or alternatively stimulated with the GTPase activator CN04
(1µg/ml) (Cytoskeleton, Inc.), which served as a positive control
(Yamamoto et al., 2008). To quantify RhoA and Rac1 GTPase
activity, a commercially available G-LISA RhoA Activation Assay
kit and G-LISA Rac1 Activation Assay kit (Cytoskeleton Inc.,
Denver, CO) were used.
Flow Cytometry
MDM were untreated or pre-treated with PARPi or Rac1/RhoA
inhibitors for 1 h prior to stimulation for 5min by adsorption
with HIV-1ADA. As a positive control, cells were stimulated
with the GTPase activator CN04 (1µg/ml) (Cytoskeleton,
Inc.). Cells were washed and fixed for 10min with 4%
methanol-free formaldehyde (Thermo Scientific, Rockford,
IL). Cells were stained overnight in 1X Permeability Buffer
(eBioscience Inc.) diluted in Flow Buffer (BD Biosciences, San
Jose, CA) with antibodies against phosphorylated-cofilin (Cell
Signaling Technology, Inc., Danvers, MA) and total cofilin-
APC (Novus Biologicals, Littleton, CO). Following primary
antibody incubation, the cells were washed and incubated in flow
buffer containing isotype control antibody (BD Biosciences) or
fluorophore-conjugated secondary antibody (eBioscience Inc.).
A FACS BDCanto II flow cytometer (BDBiosciences) and FlowJo
software were used to obtain and analyze data (Tree Star, Inc.,
Ashland, OR). Data were collected from at least 10,000 events and
repeated for MDM from three different donors.
Quantification of F-actin and G-actin
MDM were treated with PARPi for 1 h prior to HIV-1ADA
adsorption for 5min. Cells were washed with ice-cold PBS and
fixed for 10min as described above. Filamentous actin (F-actin)
was stained by Acti-stain™ 488 phalloidin (Cytoskeleton) and
globular actin (G-actin) was stained with DNase 1-Alexa 591
(Life Technologies) according to the manufacturer’s instructions.
A FACS BD Aria flow cytometer (BD Biosciences) and FlowJo
software were used to obtain and analyze data. The ratio of F-
actin to G-actin was calculated by dividing mean fluorescent
intensity (MFI) of F-actin by the MFI of G-actin in a cell
population. Data were collected from at least 20,000 events and
repeated twice with MDM from different donors.
Viability Assay
MDM were treated with PARPi for 24 h. Cells were washed
with PBS and viability was performed using the Live-Dead
assay (Life Technologies), according to the manufacturer’s
recommendations.
Statistical Analysis
Data are expressed as the mean ± SEM of experiments
conducted multiple times. One-Way analysis of variance with
FIGURE 2 | PARP inhibition reduces HIV-1 reverse transcriptase
(RT) activity and HIV-1 LTR activity in human MDM infected
with different tropism HIV-1 strains. RT activity assays performed
on HIV-infected MDM treated with PARPi or AZT either for 24 h prior
to HIV infection (A,C) or immediately after (B,D) HIV infection. MDM
were infected with M-tropic JRFL strain (A,B) or dual-tropic strain
89.6 (C,D). Treatments with PARP inhibitors (PARPi) or AZT were
replenished every 24 h. The results are shown as the mean value ±
SEM from three independent experiments utilizing MDM prepared
from different donors. Data are presented as the percent of HIV-only
control. (*p = 0.05, **p = 0.01, ***p = 0.005, ****p < 0.0001, ns, not
significant).
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Dunnet’s post-hoc tests was used for multiple group comparisons
(luciferase, FACS, HIV-1 RT assays). Prism v6.0c software
(GraphPad Software Inc., San Diego, CA) was used for statistical
analyses. A p-value of p < 0.05 was considered significant.
Results
PARP Inhibition Diminishes HIV-1 Infection of
MDM
Given the gene regulatory role that PARP suppression plays in
immune cells, we examined whether specific PARP inhibitors
FIGURE 3 | Inhibition of PARP diminishes secretion of p24 HIV-1 gag
protein in human MDM infected with different HIV-1 strains. p24 ELISA
was performed on supernatants from HIV-infected MDM treated with PARPi or
AZT for 24 h prior to HIV infection. MDM were infected with M-tropic strains
ADA (A) and JRFL (B) or the dual-tropic strain 89.6 (C). Treatments with PARP
inhibitors (PARPi) or AZT were replenished every 24 h. The results are shown
as the mean value ± SEM from three independent experiments utilizing MDM
prepared from different donors. Data are presented as percent of HIV-only
control. (*p = 0.05, **p = 0.005, ***p < 0.001, ns, not significant).
may affect HIV-1 replication. Differentiated MDM were
infected with three strains of HIV-1: two M-tropic, HIV-1ADA
(Ebenbichler et al., 1995) and HIV-1JRFL (Naif et al., 2002) and
one dual-tropic (HIV-189.6) (Yi et al., 1999) for 4 h; HIV-1 RT
activity was measured after 7 days (as described in Materials and
Methods). MDM were treated prior to HIV-1 infection or 4 h
after HIV-1 infection with the PARP inhibitors as specified in
Figure 1. Pretreatment with the PARPi AZD, EB47, and PJ34
resulted in 50± 3% reduction in HIV-1ADA RT activity in MDM,
whereas AIQ and BMN led to 40 ± 5% decrease (Figure 1A).
When PARPi were added after HIV-1ADA infection, AIQ and
PJ34 diminished HIV-1 RT activity by almost 80%, while AZD
and EB47 treatment resulted in 60 ± 2% and 25 ± 4% reduction
in HIV-1 RT activity, respectively (Figure 1B). Of note, BMN
treatment did not produce significant diminution in RT activity.
The RT inhibitor, AZT (10µM), significantly attenuated RT
activity when added both prior to infection and after infection
(Figures 1A,B). Pretreatment with the PARPi AZD resulted in
48 ± 3% reduction in HIV-1JRFL or HIV-189.6 RT activity in
MDM, whereas EB47 and PJ34 led to a 20 ± 2% decrease
(Figures 2A,C). When PARPi were added after HIV-1JRFL or
HIV-189.6 infection, AZD, EB47, and PJ34 diminished HIV-1
RT activity by 20–30%, while AIQ treatment resulted in 35 ±
2% reduction in HIV-1JRFL RT activity and did not produce
FIGURE 4 | Inhibition of Rho or Rac GTPase decreases HIV-1 reverse
transcriptase (RT) activity in HIV-1 infected human macrophages
(MDM). RT activity assays performed on HIV-infected MDM treated with Rho
and Rac GTPase inhibitors, CT04, NSC, or AZT either for 24 h prior to HIV
infection (A) or immediately after (B) HIV infection. The results are shown as
the mean value ± SEM from three independent experiments utilizing MDM
prepared from different donors. Treatments with Rho and Rac GTPase
inhibitors or AZT were replenished every 12 h. (***p = 0.005, ****p < 0.0001).
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significant diminution in HIV-189.6 RT activity, respectively
(Figures 2B,D). Inhibition of PARP in MDM resulted in a
significant reduction in secretion of p24 HIV-1 gag protein in all
three strains (Figure 3). Since PARP inhibition was not strain-
specific, HIV-1ADA was used in succeeding experiments. These
results support the possible use of PARPi as potential anti-HIV-1
therapy.
Inhibition of Small Rho GTPases Affects HIV-1
Infection
Our group recently demonstrated that PARP inhibition
suppresses activation of small Rho GTPases (Rom et al., 2015).
Since small Rho GTPases are important in HIV-1 infection in
different cell lines (Wang et al., 2000; Zoughlami et al., 2012),
we decided to investigate whether small Rho GTPase inhibition
would affect HIV-1 infection in primary MDM. Differentiated
MDM were infected for 4 h and treated 1 h prior to or 4 h after
HIV-1 infection with CT04 (1µg/ml) and NSC (75µM), RhoA
or Rac1 GTPase inhibitors, respectively. HIV-1 RT activity
was measured after 7 days infection. Inhibition of both RhoA
and Rac1 GTPases resulted in 48 ± 2% decrease in HIV-1 RT
activity, when inhibitors were applied prior to HIV-1 infection
of MDM (Figure 4A), whereas post-infection treatment with
Rho GTPase inhibitors led to 85 ± 3% diminution in HIV-1
RT (Figure 4B). The degree of inhibition in HIV-1 RT activity
by small Rho GTPase inhibitors correlates with the extent of
the effect of PARPi (Figure 1). These data support a connection
between a role for PARP inhibition and GTPase activation in
HIV-1 infection.
Small GTPase Activation Is Diminished in MDM
upon PARP Inhibition
Since RhoA and Rac1 play critical roles in influencing the
replication of HIV-1 (Wang et al., 2000; Stolp and Fackler,
2011; Costantino et al., 2012), we explored the possibility that
PARPi would suppress their activity in MDM activated with
relevant stimuli. To detect the active, GTP-bound form of
RhoA or Rac1, we used a commercially available G-LISA kit
(Cytoskeleton Inc.). Induction of integrin signaling (leading
to GTPase activation) can be achieved by cross-linking with
antibodies mimicking engagement by HIV-1. Cross-linking of
CXCR4 in MDM induced 2.5- and 2.8-fold increase of RhoA
and Rac1 activity, respectively (Figures 5A,B). Of note the
negative control (non-immune IgG) had no effect on small
GTPase activation. Treatment with the PARPi, AZD and BMN,
resulted in 40 and 55% reduction in RhoA activation, respectively
(Figure 5A). RhoA specific inhibitor, CT04, treatment led to 50±
3% decrease in RhoA activation. Rac1 activation was diminished
by 40 ± 5% when pretreated with BMN. Rac1 specific inhibitor,
NSC, treatment led to 51 ± 4% decrease in Rac1 activation
(Figure 5B). In summary, we have shown that PARPi alters RhoA
and Rac1 activation in MDM.
Inactivation of PARP Prevents Dephosphorylation
of Inhibitory Sites of Cofilin
Serial engagement of the primary viral receptor, CD4, and
the co-receptor, CXCR4 or CCR5, are required for HIV entry
FIGURE 5 | PARP inhibition decreases Rac1 activation in primary MDM.
(A) RhoA and (B) Rac1 GTPases activity was measured in primary MDMs.
GTPases were activated by cross-linking (x-linking) of the CXCR4 receptor with
α-CXCR4 antibody (mimicking HIV-1 engagement with macrophage cells). The
level of RhoA or Rac1 activity in non-treated cross-linked cells was assigned a
value of 1 to calculate the relative ratio of activation. The results are shown as
the mean value ± SEM from three independent experiments. (*p < 0.05,
**p < 0.005, and ***p < 0.0001 vs. cross-linked but inhibitor untreated cells).
into the cell (Maddon et al., 1986; Cocchi et al., 1995; Feng
et al., 1996; Spear et al., 2012). This binding of HIV to
respective receptors results in viral fusion, where the viral
core is delivered into the cytoplasm. Furthermore, intracellular
transport of the incoming genome toward the nucleus and of
virions to budding sites requires functional interactions with the
host actin cytoskeleton (Stolp and Fackler, 2011). Chemokine
receptor signaling typically results in activation of Rho GTPases,
which coordinate actin filament formation and cell motility,
requiring efficient disassembly of preexisting actin filaments.
A search for proteins that regulate filamentous and globular
actin levels revealed an increase in the levels of an inactive
phosphorylated form (phospho-serine 3) of the F-actin-severing
protein, cofilin (Arber et al., 1998). After detection of cofilin
phosphorylation in MDM without stimulation, we examined
the dynamics of cofilin phosphorylation in cells undergoing
changes in actin cytoskeletal reorganization during the first 5min
of HIV-1 contact (Costantino et al., 2012). HIV-1 interaction
with MDM led to a 4.8-fold decrease in cofilin phosphorylation
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FIGURE 6 | PARP inhibition increases inhibitory site Ser3-cofilin
phosphorylation. (A) Representative contour plots from flow cytometry
analysis of phospho-Ser3-cofilin and total cofilin in MDM stimulated by
addition of HIVADA for 5min. MDM were treated with or without PARPi for 1 h
prior to HIVADA introduction. Rho and Rac GTPase inhibitors, CT04, NSC,
and Rho/Rac activator, CN04, were used as controls. (B) Quantitation of
phosphor-Ser3-cofilin cells in human MDM. The results are shown as the
mean value ± SEM (*p < 0.05 vs. HIV-stimulated but inhibitor untreated cells)
from three independent experiments utilizing MDM prepared from different
donors.
of the inhibitory site of serine 3 (Figure 6). As a positive
control, we used the Rho GTPase activator, CN04, which
resulted in total cofilin dephosphorylation of the inhibitory site
(Figure 6). However, treatment of MDM with PARPi led to 13
and 16% increases in phosphorylation levels of the inhibitory
site phospho-serine 3. The effects of RhoA and Rac1 specific
inhibitors, CT04 and NSC, were similar to that of PARPi.
Together, these results strongly suggest that PARP inhibition
affects the actin-binding protein, cofilin, via RhoA and Rac1
suppression.
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FIGURE 7 | PARP inhibitors suppress activation of small GTPases
in MDM and affect actin rearrangements. (A) Representative
histograms from flow cytometry analysis of F-actin and G-actin in MDM
stimulated by addition of HIVADA for 5min. MDM were treated with or
without PARPi for 1 h prior to HIVADA introduction. Rho and Rac
GTPase inhibitors, CT04, NSC, and Rho/Rac activator, CN04, used as
controls. (B) Graphical representation of F-actin to G-actin ratios. The
results are shown as the mean value ± SEM (*p < 0.05 vs.
HIV-stimulated but inhibitor untreated cells) from three independent
experiments utilizing MDM prepared from different donors.
PARP Inhibition Affects Actin Cytoskeleton
Rearrangements
Actin rearrangements triggered by HIV-1 are regulated by
severing cofilin, thus dissociating and facilitating actin filament
depolymerization (Arber et al., 1998; Costantino et al., 2012).
Since PARP inhibition affected dephosphorylation of the
inhibitory site and thus activation of cofilin, we investigated
actin rearrangements in MDM during the first 5min of HIV-
1 contact (Costantino et al., 2012) by flow cytometry. For
comparison of F/G-actin ratios inMDM, F-actin was stained with
phalloidin and G-actin was stained with DNAse I during HIV-
1-adsorption to MDM with or without PARPi. F-actin staining
increased upon contact with HIV-1, whereas G-actin staining
decreased (Figure 7A). The Rho GTPase activator, CN04, which
was used as a positive control, showed similar effects on F-
and G-actin staining patterns (Figure 7A). MFI for F-actin
and G-actin from different stimulations or treatments were
used to calculate F/G-actin ratios. HIV-1 adsorption to MDM
resulted in a 4-fold increase in F/G-actin ratio (Figure 7B).
PARPi such as AIQ and BMN attenuated by 95 ± 3%
and AZD completely blocked actin rearrangements in HIV-1-
infected MDM (Figure 7B). The effects of RhoA and Rac1-
specific inhibitors, CT04 and NSC, were similar to that of
PARPi. Taken together, these results strongly indicate that PARP
inhibition affects the actin cytoskeleton via RhoA and Rac1
inhibition.
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FIGURE 8 | PARP inhibitors suppress HIV-1 LTR activation in
macrophages (MDM) by repressing NFkB activation. (A) Tat-expressing
plasmid and HIV-1 LTR-containing plasmid were used to transfect MDM with
or without treatment with PARPi. Treatments were introduced 3 h
post-transfection. (B) Single round HIV-1 infection of TZM-bl reporter cells
pre-treated with PARPi or AZT. (C) HIV-1 LTR-containing plasmid was used
to transfect MDM with or without treatment with PARPi. Treatments were
introduced 1 h before PMA or TNFα. (D) Luciferase reporter plasmid (with/out
NFkB-binding site) was used to transfect MDM with or without treatment
with PARPi. The results shown are mean value ± SEM for quadruplicate
cultures of MDM prepared from different donors (*p < 0.05 inhibitor untreated
cells vs. stimulated cells in A,C,D or vs. HIV-1 infected cells in B).
PARPi Inhibit the Activity of HIV-1 LTR
To access the possibility that HIV-1 LTR activity is affected
by inactivation of PARP, we performed single-round HIV-1
infection using the reporter line, TZM-bl cells. PseudotypedHIV-
1 virions, lacking the envelope protein, were produced and TZM-
bl cells were infected as described in the Materials and Methods
section. Since TZM-bl cells contain the β-gal reporter gene under
the control of the HIV-1 LTR, we could measure its activity
(Ramirez et al., 2013). The infection was allowed to continue
for 4 h at which point the media containing virus was removed
and changed to medium containing PARPi. AIQ treatment led to
a 40 ± 5% reduction in β-gal-activity in HIV-1 infected TZM-
bl cells as related to untreated (Figure 8B). PJ34 resulted in a
30 ± 3% inhibition. LTR acts as a switch in virus replication
and can be triggered by agents such as Tat, TNFα, or PMA
(Kameoka et al., 1999a,b; Rom et al., 2010). To further confirm
the HIV-1 LTR inhibition, MDM were co-transfected with
pEYFP-Tat101 plasmid or pYFP-C1 (control) in the presence or
absence of PARPi and 24 h later analyzed for luciferase activity.
Tat protein is a transactivating factor comprised of 86–101 amino
acids encoded by HIV-1. The importance of HIV-1 Tat in the
viral replication cycle and in the pathogenesis of AIDS is well
documented (Rom et al., 2011). Indeed, HIV-1 Tat increased
HIV-1 LTR activity by 4.2-fold, which was attenuated by PARPi
application. The PARPi, ABA, reduced HIV-1 LTR activation by
65%, while PJ34, AZD, and EB47 completely abolished HIV-1
LTR activity (Figure 8A). Alternatively, MDM were transfected
with HIV-1 LTR-luciferase reporter plasmid and then stimulated
with TNFα or PMA for 24 h. Both TNFα and PMA stimulation
led to 3-fold increases in HIV-1 LTR activity, which was entirely
abrogated by selective PARPi inhibition (Figure 8C). Various
host transcription factors have been shown to bind to and activate
the LTR of HIV-1; NFκB protein was one of them (Kaufman et al.,
1992). We and others have described PARP to be a NFκB co-
activator in different types of cells during inflammatory processes
and cancer (Kameoka et al., 2000; Hassa and Hottiger, 2002;
Hauser et al., 2006; Liu et al., 2012; Nakagawa et al., 2015; Rom
et al., 2015). To prove a connection of PARP inhibition to NFκB
activation in macrophages, we used a luciferase reporter system
where only the active form of NFκB would be able to turn on
the promoter. Transfected cells were stimulated with TNFα and
PMA in the absence or presence of PARPi and the medium
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was collected for reporter assay. Stimulation with TNFα resulted
in a 2.1-fold increase in NFκB activation, whereas PMA led to
a 4.2-fold up-regulation (Figure 8D). PARPi attenuated NFκB
activation by 85–89% and up to 95%, in PMA- and TNFα-
stimulated MDM, respectively (Figure 8D). Our results indicate
that inhibitors of PARP decrease viral replication by antagonizing
the HIV-1 LTR via disruption in NFκB signaling.
Discussion
HIV-1 infection of macrophages plays an important role in the
development of HAND (Kaul and Lipton, 2006). Production
of pro-inflammatory molecules (like CCL2, CD40L, IP-10, IL-
8) by HIV-1 infected macrophages is associated with HAND
progression (Letendre et al., 2011). Therefore, approaches
curtailing both virus replication and limiting inflammatory
responses are necessary to prevent neuro-cognitive decline seen
in HIV-1 infection. Our previous work demonstrated anti-
inflammatory and barrier protecting effects of PARP inhibition
in brain endothelial cells (Rom et al., 2015) and macrophages
(unpublished observations). Here, we report efficient suppression
of HIV-1 replication in human macrophages by PARPi and
several potential mechanisms underlying this phenomenon.
There are few reports suggesting involvement of PARP
in HIV-1 replication. PARP was required for efficient HIV-1
integration in murine PARP-1 knock out embryonic fibroblasts
(Ha et al., 2001). PARP inactivation was shown to play a role
in the HIV-1 life cycle, where PARP contributed to HIV-1 LTR
function in U1 cells (Kameoka et al., 1999b, 2005) and competed
for binding to TAR RNA with p-TEFb in in vitro gel retardation
studies (Parent et al., 2005).
The involvement of PARP in HIV-1 gene expression seems
to be complicated depending on the inhibitors used in the study
and/or the system used, including cells and inducers. Our results
revealed that PARPi diminished HIV-1 replication in primary
human MDM, whether applied prior to or after infection. No
HIV-1 strain specificity was noted. Post-infection addition of
PARPi, such as AIQ, AZD, and PJ34, had a much stronger effect
on HIV-1 infection, than when inhibitors were added to MDM
before infection, whereas EB47 had the same effects on HIV-
1 infection. Interestingly, BMN had a significant effect only in
pretreatment and not after. There is a possibility that different
compounds have diverse kinetics in absorption as well as in
retention in the cell.
HIV-1 infection could be diminished at different steps
(interactions with receptors, receptor internalization,
cytoskeleton rearrangement, and efficient integration). HIV-1
entry into target cells requires serial engagement of the primary
viral receptor, CD4, and co-receptor, CXCR4 or CCR5 (Maddon
et al., 1986; Cocchi et al., 1995; Feng et al., 1996; Spear et al.,
2012). HIV binding, receptor clustering and intracellular
transport of the viral genome toward the nucleus as well as to
budding sites happens to necessitate functional interactions with
the host actin cytoskeleton (Stolp and Fackler, 2011). It has been
shown in CD4+ lymphocytes that suppression of cytoskeleton
regulators (Arp2/3 and WAVE2) prevented HIV-1 infection
diminishing its intracellular migration (Spear and Wu, 2014).
Our data indicate that PARPi prevented HIV-1 from hijacking
the cytoskeletal cell compartment, shown by complete blockage
of F/G-actin transition by preventing the actin severing protein,
cofilin, to become activated via attenuation of RhoA/Rac1
signaling (Figure 9).
FIGURE 9 | Effect of PARP inhibition on HIV-1 infection and replication.
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In addition, PARP, being a co-activator of NFκB (Kameoka
et al., 1999b, 2005), prevented HIV-1 gene transcription by
obstructing HIV-1 LTR activation (Figure 9). The transcription
factor NF-κB plays a critical role in immune and inflammatory
responses. HIV-1 is known to produce inflammatory responses
in wide variety of cells in different organs: brain, lungs, intestine,
and kidneys, etc. The anti-inflammatory effects of PARP have
been demonstrated in numerous in vivo and in vitro studies
(Kraus and Lis, 2003; Erdélyi et al., 2005; Liu et al., 2012), some
of which are due to effects of PARP on NF-κB function (Zerfaoui
et al., 2009, 2010; Swindall et al., 2013).
Several PARP inhibitors are at different stages of cancer
treatment clinical trials (Cavone et al., 2011) including two
used in our study. Talazoparib (BMN) and Olaparib (AZD)
showed suppressive effects on HIV-1 replication. PARPi might
increase the therapeutic potential of currently used anti-retroviral
treatments to reduce peripheral viral load. In addition to anti-
retroviral potential of PARPi, the anti-inflammatory effects of
PARP suppression in rodent models of meningitis and stroke,
brain injury, and MS are important for HAND treatment as they
attenuate leukocyte infiltration across the blood brain barrier
and neuroinflammation (Lenzsér et al., 2007; Farez et al., 2009;
Lescot et al., 2010; Rom et al., 2015). Approval of PARPi for
clinical trials by the FDA assures fast translation of PARPi for
therapy of immune/inflammatory disorders, HAND and other
HIV-associated end-organ dysfunctions.
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